Aplastic Anemia Clinical Trials and Treatments

Aplastic anemia (AA) is a rare acquired or inherited bone marrow failure syndrome characterized by peripheral pancytopenia (anemia, thrombocytopenia, neutropenia) with hypocellular bone marrow and reduced hematopoietic precursors. Pathophysiology involves loss of hematopoietic stem cell and progenitor cell populations from multiple potential mechanisms: immune-mediated destruction (~50% of acquired cases via autoreactive T-cell cytotoxicity), direct toxic injury to stem cells (drug-induced from chemotherapy, antibiotics like chloramphenicol), viral infections (especially hepatitis-associated aplastic anemia), radiation exposure, chemical exposures (benzene), or genetic predisposition in inherited forms (Fanconi anemia, dyskeratosis congenita). The condition manifests with symptoms of anemia (fatigue, dyspnea, exercise intolerance), bleeding from thrombocytopenia (petechiae, mucosal bleeding, intracranial hemorrhage), and infections from neutropenia including fever and opportunistic infections.

The most common symptoms of Aplastic Anemia include Fatigue and dyspnea from anemia, Petechiae and bleeding from thrombocytopenia, Infections from neutropenia, Fever without obvious source, Splenomegaly occasionally present, among others. Aplastic Anemia affects approximately 1-2 cases per 1 million people per year. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Aplastic Anemia from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporine induces complete or partial remission in approximately 70% of patients, with response rates higher in younger patients. Allogeneic hematopoietic stem cell transplantation offers curative potential, particularly in younger patients (<40 years) with matched sibling donors achieving ~85% long-term survival.

Yes. As of September 2026, Trial Friend lists 3 FDA-approved drugs used to treat Aplastic Anemia: ATGAM (antithymocyte globulin (horse)), first approved in 1981; Neoral (cyclosporine), first approved in 1983; and Promacta (eltrombopag), first approved in 2014.

Each has its own page with what the label covers, side effects and how it is given, and the Treatments section of this page adds any further approved drugs found in FDA labeling data.

Aplastic Anemia is an acquired condition, not an inherited one. Acquired aplastic anemia is immune-mediated; inherited marrow failure syndromes (Fanconi anemia, telomere diseases) must be excluded, especially in younger patients. The condition affects approximately 1-2 cases per 1 million people per year.

Eligibility for Aplastic Anemia clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Aplastic Anemia clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.